 |
|
Treatment With UV-B for Psoriasis and Nonmelanoma Skin Cancer
A Systematic Review of the Literature
Pieternel C. M. Pasker-de Jong, PhD;
Gina Wielink, PhD;
Pieter G. M. van der Valk, MD;
Gert-Jan van der Wilt, PhD
Arch Dermatol. 1999;135:834-840.
Background In a cost-effectiveness study currently being conducted of short-contact anthralin treatment for psoriasis in an outpatient setting as compared with the standard treatment with UV-B radiation, the excess incidence (IDD) of skin cancer due to exposure to UV-B could not be ascertained because the study did not last long enough. A meta-analysis of published data was deemed appropriate.
Objective To quantify the IDD of nonmelanoma skin cancer as a function of the total dose of UV-B and specific for time since first exposure, age at first treatment, and other treatments received.
Methods Systematic review of the literature with meta-analysis of all available evidence published in English, French, German, or Dutch between 1980 and 1996.
Results Four articles contained information that enabled us to calculate an overall IDD of nonmelanoma skin cancer. The estimates varied between -0.6 and 2 extra skin cancers per 100 patients with psoriasis treated with UV-B phototherapy per year. However, these estimates were calculated under several assumptions, and do not allow for the construction of a dose-response model specific for time since exposure or age at first treatment. A model based on animal data suggests that a total of 5 excess skin cancers can be expected per 100 treated in the 60 years after the start of treatment with 500 minimum effective doses of UV-B per year from age 25 years.
Conclusions The available evidence is insufficient for quantifying the IDD of nonmelanoma skin cancer in patients with psoriasis treated with UV-B radiation. However, it seems unlikely that the excess risk exceeds 2% per year. As yet, it is not possible to assess at what level of exposure this IDD occurs, or how long after exposure excess risk is present.
From the Departments of Epidemiology (Dr Pasker-de Jong) and Medical Technology Assessment (Drs Wielink and van der Wilt), and the Department of Dermatology, University Hospital St Radboud (Dr van der Valk), University of Nijmegen, Nijmegen, the Netherlands.
RELATED ARTICLE
Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 1999;135(7):761-762.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Psoriasis: advances in pathophysiology and management
MacDonald and Burden
Postgrad. Med. J. 2007;83:690-697.
ABSTRACT
| FULL TEXT
The Safety and Efficacy of the 308-nm Excimer Laser for Pigment Correction of Hypopigmented Scars and Striae Alba
Alexiades-Armenakas et al.
Arch Dermatol 2004;140:955-960.
ABSTRACT
| FULL TEXT
Are Patients With Psoriasis Susceptible to the Classic Risk Factors for Actinic Keratoses?
Paltiel et al.
Arch Dermatol 2004;140:805-810.
ABSTRACT
| FULL TEXT
The Risk of Malignancy Associated With Psoriasis
Margolis et al.
Arch Dermatol 2001;137:778-783.
ABSTRACT
| FULL TEXT
UVB Therapy for Psoriasis: The Skin Cancer Risk Is Unknown
Journal Watch Dermatology 1999;1999:3-3.
FULL TEXT
|
